Immorta Bio Inc., a company dedicated to advancing scientific approaches to longevity, announced the publication of its international patent application for SenoVaxTM, an innovative senolytic immunotherapy. The patent application, titled “Senescence Vaccine,” was made public on November 25, 2025, and describes a proprietary method for stimulating the immune system to eliminate senescent cells—those dysfunctional cells that contribute to aging, inflammation, and tumor growth.
The release of this patent positions Immorta Bio at the forefront of addressing two significant challenges of aging: the buildup of senescent cells and cancer progression. SenoVaxTM has shown promising results in preclinical trials, demonstrating a potent capability to reduce various cancer types, including lung, breast, brain, skin, and pancreatic cancers, across multiple in vivo models.
Innovative Approach to Aging and Cancer Treatment
According to the company, SenoVaxTM represents a first-in-class immunotherapy that not only targets age-related decline but also disrupts the tumor-supportive microenvironment essential for cancer survival. Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio, highlighted the dual-action nature of this therapy, stating, “By killing senescent cells, we reduce aging biology itself while simultaneously disrupting the tumor-supportive microenvironment required for cancer survival.”
In addition to SenoVaxTM, Immorta Bio is developing StemCellRevivifyTM, a platform for introducing young, organ-specific progenitor and mesenchymal stem cells aimed at restoring the body’s regenerative capabilities. Together, these two platforms target the fundamental drivers of aging: impaired clearance of damaged cells and the loss of tissue regeneration.
Dr. Boris Reznik, Chairman and CEO of Immorta Bio, emphasized the importance of this research, stating, “Cancer is the most prevalent disease of aging, and SenoVaxTM allows us to attack both aging biology and tumor biology at the same time.” The company is focused on establishing the safety and efficacy of SenoVaxTM in advanced cancer patients, with plans to expand its applications to age-related conditions.
Promising Preclinical Results
Preclinical studies have shown compelling evidence supporting the efficacy of SenoVaxTM. The company reports positive outcomes across various cancer models and models of aging and frailty. Notably, there have been indications of over 100% extension of lifespan and improvements in healthspan, further reinforcing the viability of Immorta Bio’s dual-platform strategy.
The publication of the international patent application strengthens Immorta Bio’s standing as a leader in the development of therapies that address aging and its associated diseases. As the company moves forward, it aims to integrate immunotherapy with regenerative medicine to enhance health and longevity.
Immorta Bio Inc. continues its mission to restore youthful biology and extend healthy lifespans through its innovative approaches. For more information, the company can be reached at +1 (305) 632-2939 or via their website at www.ImmortaBio.com.
